Results 101 to 110 of about 2,479 (207)

Loss of Melanoregulin (MREG) Enhances Cathepsin-D Secretion by the Retinal Pigment Epithelium [PDF]

, 2013
Cathepsin-D (Cat-D) is a major proteolytic enzyme in phagocytic cells. In the retinal pigment epithelium (RPE), it is responsible for the daily degradation of photoreceptor outer segments (POSs) to maintain retinal homeostasis.
Boesze-Battaglia, Kathleen, Bragin, Alvina, Frost, Laura S., Lopes, Vanda S., Mitchell, Claire H., Stefano, Frank P., Williams, David S.   +6 more
core   +1 more source

Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response

Pain and Therapy
Introduction Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide, is indicated for preventive treatment of migraine in adults. Real-world evidence assessing the effect of fremanezumab on migraine-related medication use,
Dawn C. Buse, Lynda J. Krasenbaum, Michael J. Seminerio, Elizabeth R. Packnett, Karen Carr, Mario Ortega, Maurice T. Driessen   +6 more
doaj   +1 more source

Switching anti-CGRP monoclonal antibodies in chronic migraine:real-world observations of erenumab, fremanezumab and galcanezumab [PDF]

Objectives: The anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP-mAb) are effective in migraine; however, few studies have examined the benefit of switching from one anti-CGRP-mAb to another.
Crossingham, Ginette, Gordon, Alexander, Stuckey, Rebecca, Talbot, Jamie, Weatherby, Stuart, Wood, Natasha   +5 more
core   +1 more source

Fremanezumab for migraine [PDF]

Australian Prescriber, 2020
openaire   +2 more sources

Glycerol Trinitrate Acts Downstream of Calcitonin Gene-Related Peptide in Trigeminal Nociception—Evidence from Rodent Experiments with Anti-CGRP Antibody Fremanezumab

Cells
Calcitonin gene-related peptide (CGRP) and nitric oxide (NO) have been recognized as important mediators in migraine but their mechanisms of action and interaction have not been fully elucidated.
Nicola Benedicter, Birgit Vogler, Annette Kuhn, Jana Schramm, Kimberly D. Mackenzie, Jennifer Stratton, Mária Dux, Karl Messlinger   +7 more
doaj   +1 more source

Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study

Patient Preference and Adherence
Oralee J Varnado,1 Brenna L Brady,2 Anthony J Zagar,1 Yvonne P Robles,2 Margaret Hoyt1 1Eli Lilly and Company, Indianapolis, IN, USA; 2Merative, Ann Arbor, MI, USACorrespondence: Oralee J VarnadoValue, Evidence, and Outcomes, Eli Lilly and Company, Lilly
Varnado OJ, Brady BL, Zagar AJ, Robles YP, Hoyt M   +4 more
doaj  

Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review [PDF]

Background: Migraine is the second most common prevalent disorder worldwide and is a top cause of disability with a substantial economic burden. Many preventive migraine medications have notable side effects that affect different body organs.
Aksentyte, Aiva, Brown, Anna, Davies, Natasha, Duncan, Callum, Matharu, Manjit, Mistry, Hema, Naghdi, Seyran, Underwood, Martin   +7 more
core  

Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study

Cephalalgia Reports
Background: Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM).
Hsiangkuo Yuan, Fred Cohen, Maurice T Driessen, Lynda J Krasenbaum, Mario Ortega, Mary Hopkins, Michael J Marmura   +6 more
doaj   +1 more source

Fremanezumab in the treatment of migraines: evidence to date.

Journal of pain research, 2019
Calcitonin gene-related peptide (CGRP) is a major player in migraine pathophysiology, and CGRP monoclonal antibodies including fremanezumab may be a safe effective preventive therapy. Phase IIb studies in episodic migraine (EM) and chronic migraine (CM) demonstrated efficacy at both the monthly 225 mg and quarterly 675 mg doses.
Robblee,Jennifer, VanderPluym,Juliana
openaire   +4 more sources

Real-World effectiveness after initiating fremanezumab treatment in Brazilian patients with episodic and chronic migraine [PDF]

Background: Migraine is a debilitating condition, estimated to affect 30 million people in Brazil. Prevention may be considered for both episodic (EM) and chronic (CM) migraine and represents a real challenge in patient management.
Carvalho, João Jose Freitas de, Kaup, Alexandre   +1 more
core   +1 more source